TRUALT TruAlt Bioenergy Q2 FY27 results (Jul–Sep 2026) and concall
TruAlt Bioenergy demonstrated massive scale expansion in Q2 FY27, with revenue jumping 606% YoY to ₹811 crores and PAT turning around to ₹35 crores, supported by expanded capacity and higher allocation volumes. However, profitability faced margin pressure sequentially due to a 25-30% surge in maize prices and raw material availability constraints. The company is actively diversifying through dual-feed plant flexibility, expanding its compressed biogas (CBG) capacity via JVs with Sumitomo and GAIL, and divesting non-core assets such as the Badami ethanol unit to optimize capital structure.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 605.2%, net profit up 192.1% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 415 | 907 | 304 | 115 | 713 +72% | 596 −34% | 627 +106% | 811 +605% |
| EBITDA | 125 | 154 | 42 | -5 | 134 +7% | 129 −16% | 133 +217% | 101 +2120% |
| Net profit | 75 | 112 | 5 | -38 | 69 −8% | 69 −38% | 59 +1080% | 35 +192% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
